Senores Q1 beats on regulated markets; branded generics target cut a credibility gap
Revenue and profit surged, but management slashed domestic branded sales goals by ~40% without explaining why.
The numbers
- Q1 FY27 revenue hit ₹180 cr, up 36% YoY, driven by 42% growth in regulated markets.
- Net profit rose 44% to ₹30 cr, consistent with prior quarters' strength.
- EBITDA margin touched ~30%, up sharply YoY.
- The trailing P/E of 50.6x leaves little room for error.
- Approved ANDAs rose 93% to 58, with 23 already commercialized.
Management's story
- FY27 revenue growth guided at 30-40%, PAT growth at 50-60%.
- India domestic branded generics target cut to ₹50-60 cr from earlier ₹80-100 cr, attributed to a profitability-first strategy.
- 35 ANDAs slated for commercialization over the next 18-20 months.
- Capex guided at ₹100-130 cr; sterile injectable pilot deferred to H2 FY27.
“Our India domestic business is expected to do 50-60 crores this year. The growth has moderated because of this change in strategy.”
— Swapnil Shah, Managing Director, Jul 2026 call
Where they diverge
The reported quarter is strong – revenue up 36%, margins near 30% – and aligns with management's broader growth guidance. But the branded generics target was slashed by roughly 40% from prior projections of ₹80-100 cr to ₹50-60 cr, with no reconciliation provided. Management's explanation of a shift to profitability over volume does not bridge the gap. The rest of the story – ANDA pipeline, US commercialization, emerging market scale – remains intact, but guidance credibility takes a hit.
The full read
Senores delivered another quarter of solid execution: revenue of ₹180 cr, up 36% YoY, and net profit of ₹30 cr, up 44%. Regulated markets grew 42%, and EBITDA margins hit nearly 30%. These numbers were well within management's own guidance, and the market has already paid for this trajectory with a 50.6x trailing P/E. The real story, however, is the branded generics guidance flip. In November 2025, management projected ₹100 cr; in January 2026, ₹80-plus cr. Now the same business is expected to deliver ₹50-60 cr for FY27. The explanation – a pivot to profitability over volume – lacks a bridge to the earlier numbers. This is not a one-quarter miss; it's a broken promise on a strategic pillar. The pipeline explosion (58 approved ANDAs, 35 set to launch) and emerging market cash-flow positivity remain intact, but investors now face a choice: trust the strong execution or question the credibility of management's projections. For a stock trading at 50x earnings, the margin for error just shrank.
What we're watching
- Whether India domestic branded generics revenue tracks toward the new ₹50-60 cr range by Q3 FY27.
- ANDA commercialization pace: 35 filings to launch within 18-20 months – any delay would pressure the premium valuation.
- Capex deployment of ₹100-130 cr and the timing of the sterile injectable pilot, now deferred to H2 FY27.
- US-India trade deal outcome, which could reset tariff assumptions.